CA
GALT icon

CoreCap Advisors’s Galectin Therapeutics GALT Stock Holding History

CoreCap Advisors’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$15.1K Hold
3,890
– – ﹤0.01% 1920
2026
Q2 		$18.1K Sell
3,890
-704
-15% -$1.82K ﹤0.01% 1839
2026
Q1 		$12.8K Hold
4,594
– – ﹤0.01% 1858
2025
Q4 		$19.1K Hold
4,594
– – ﹤0.01% 1697
2025
Q3 		$19.5K Hold
4,594
– – ﹤0.01% 1684
2025
Q2 		$9.69K Hold
4,594
– – ﹤0.01% 1882
2025
Q1 		$5.61K Sell
4,594
-3,805
-45% -$5.34K ﹤0.01% 2056
2024
Q4 		$10.8K Buy
8,399
+704
+9% +$1.69K ﹤0.01% 1742
2024
Q3 		$21.2K Buy
+7,695
New +$18.9K ﹤0.01% 1532
2024
Q2 		– Sell
-7,695
Closed -$18.4K – 1962
2024
Q1 		$18.4K Buy
+7,695
New +$14.6K ﹤0.01% 1514
2022
Q4 		$10.4K Buy
+9,195
New +$12.2K ﹤0.01% 1528
2022
Q3 		– Sell
-9,195
Closed -$12K – 1108
2022
Q2 		$12K Buy
+9,195
New +$13.2K ﹤0.01% 1420
2022
Q1 		– Sell
-9,195
Closed -$19K – 1115
2021
Q4 		$19K Buy
+9,195
New +$26.3K ﹤0.01% 1345

Other funds holding GALT

AP
Atwood & Palmer Kansas City, Missouri $1.95B AUM 16% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

CoreCap Advisors's GALT Position: Q3 2026 in Review

CoreCap Advisors held its Galectin Therapeutics (GALT) position steady in Q3 2026 at 3,890 shares worth $15.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1920.

CoreCap Advisors first reported a position in GALT in Q4 2021 and has held it in 13 quarters since. The position peaked at $21.2K in Q3 2024. 4 funds tracked by Wall St. Rank hold GALT as of Q3 2026.

  • CoreCap Advisors held 3,890 shares of Galectin Therapeutics worth $15.1K as of Q3 2026.
  • CoreCap Advisors left its Galectin Therapeutics share count unchanged in Q3 2026.
  • Galectin Therapeutics made up ﹤0.01% of CoreCap Advisors's portfolio in Q3 2026, its #1920 holding.
  • CoreCap Advisors first reported a position in Galectin Therapeutics in Q4 2021 and has held it in 13 quarters since.
  • CoreCap Advisors's Galectin Therapeutics position peaked at $21.2K in Q3 2024.
  • 4 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q3 2026.

Based on CoreCap Advisors's 13F filing for Q3 2026, filed 8 Oct 2026.